Researchers have identified that a specific somatic hypermutation (K31E) in the IGLV3-21*02/03 allele triggers VITT by causing antibodies intended for adenoviral protein pVII to cross-react with Platelet Factor 4 (PF4), explaining the pathogenesis of this rare thrombotic condition.